Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Inger Schou-Bredal, Elin Myklebust Sørensen, Kari Heitmann Kraglund, Vibeke Schou Jensen & Sigrunn Drageset. (2022) Development of the Breast Cancer Survivors Symptom Checklist for Use in Follow-Up Multidisciplinary Appointments. Patient Related Outcome Measures 13, pages 199-208.
Read now
Read now
Emilia Montagna, Paola Zagami, Marianna Masiero, Ketti Mazzocco, Gabriella Pravettoni & Elisabetta Munzone. (2021) Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. Patient Preference and Adherence 15, pages 2051-2061.
Read now
Read now
Zoe Moon, Rona Moss-Morris, Myra S Hunter, Sophie Carlisle & Lyndsay D Hughes. (2017) Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Preference and Adherence 11, pages 305-322.
Read now
Read now
Xiaoman Liu, Siew-Kee Low & Alan V. Boddy. (2016) The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors. Expert Opinion on Drug Metabolism & Toxicology 12:8, pages 851-863.
Read now
Read now
Sarah L. Shingler, Bryan M. Bennett, Joyce A. Cramer, Adrian Towse, Christopher Twelves & Andrew J. Lloyd. (2014) Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Current Medical Research and Opinion 30:11, pages 2329-2341.
Read now
Read now
Jane Bryce, Martina Bauer & Peyman Hadji. (2012) Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study. Cancer Management and Research 4, pages 105-111.
Read now
Read now
Articles from other publishers (48)
Anna M. Janssen, Joëlle Dam, Judith Prins, Laurien M. Buffart & Marijn de Bruin. (2022) Systematic adaptation of the adherence improving self‐management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach. European Journal of Cancer Care 31:6.
Crossref
Crossref
Sophie M. C. Green, David P. French, Christopher D. Graham, Louise H. Hall, Nikki Rousseau, Robbie Foy, Jane Clark, Catherine Parbutt, Erin Raine, Benjamin Gardner, Galina Velikova, Sally J. L. Moore, Jacqueline Buxton, Michelle Collinson, Rachel Ellison, Hollie Wilkes, Suzanne Hartley, Ellen Mason, Amanda Farrin, Rebecca Walwyn, Jo Waller, Daniel Howdon, Jamie Metherell & Samuel G. Smith. (2022) Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy. BMC Health Services Research 22:1.
Crossref
Crossref
Attiah Khobrani, Yasser Alatawi, Eshtyag Bajnaid, Omima Alemam, Abubakr Osman, Lina Bin Attash, Mohammed Jaffal, Mohammed AlGhanmi, Adnan Alharbi & Mohammed Alnuhait. (2022) Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study. Cureus.
Crossref
Crossref
Gelareh Sadigh, Robert J. Gray, Joseph A. Sparano, Betina Yanez, Sofia F. Garcia, Lava R. Timsina, George W. Sledge, David Cella, Lynne I. Wagner & Ruth C. Carlos. (2021) Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial. Cancer 127:14, pages 2545-2552.
Crossref
Crossref
Leah K. Lambert, Lynda G. Balneaves, A. Fuchsia Howard, Stephen L. K. Chia & Carolyn C. Gotay. (2021) Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer. Current Oncology 28:2, pages 1472-1482.
Crossref
Crossref
Mauranne Labonté, Laurence Guillaumie, Anne Dionne, Michel Dorval, Hermann Nabi, Julie Lemieux, Louise Provencher & Sophie Lauzier. (2020) Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach. Research in Social and Administrative Pharmacy 16:12, pages 1724-1736.
Crossref
Crossref
Carmen W.H. Chan, Daria Tai, Stephanie Kwong, Ka Ming Chow, Dorothy N.S. Chan & Bernard M.H. Law. (2020) The Effects of Pharmacological and Non-Pharmacological Interventions on Symptom Management and Quality of Life among Breast Cancer Survivors Undergoing Adjuvant Endocrine Therapy: A Systematic Review. International Journal of Environmental Research and Public Health 17:8, pages 2950.
Crossref
Crossref
Julie S Bedi, Rachel M Mayo, Liwei Chen, Lori Dickes, Windsor W Sherrill & Karyn Jones. (2019) Factors associated with longer endocrine therapy use by South Carolina Medicaid-insured breast cancer survivors. Journal of Oncology Pharmacy Practice 26:1, pages 36-42.
Crossref
Crossref
Sue P. Heiney, Pearman D. Parker, Tisha M. Felder, Swann Arp Adams, Omonefe O. Omofuma & Jennifer M Hulett. (2018) A systematic review of interventions to improve adherence to endocrine therapy. Breast Cancer Research and Treatment 173:3, pages 499-510.
Crossref
Crossref
Zhijun Yin, Jeremy Warner, Lijun Song, Pei-Yun Hsueh, Ching-Hua Chen & Bradley Malin. 2019. Social Web and Health Research. Social Web and Health Research
233
257
.
Leah K. Lambert, Lynda G. Balneaves, A. Fuchsia Howard, Stephen K. Chia & Carolyn C. Gotay. (2018) Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. BMC Cancer 18:1.
Crossref
Crossref
Zhijun Yin, Morgan Harrell, Jeremy L Warner, Qingxia Chen, Daniel Fabbri & Bradley A Malin. (2018) The therapy is making me sick: how online portal communications between breast cancer patients and physicians indicate medication discontinuation. Journal of the American Medical Informatics Association 25:11, pages 1444-1451.
Crossref
Crossref
Julie S. Bedi, Rachel M. Mayo, Khoa Truong, Liwei Chen, Lori Dickes, Windsor W. Sherrill & Karyn Jones. (2018) Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women. Breast Cancer Research and Treatment 171:3, pages 759-765.
Crossref
Crossref
Brittany Humphries, Stéphanie Collins, Laurence Guillaumie, Julie Lemieux, Anne Dionne, Louise Provencher, Jocelyne Moisan & Sophie Lauzier. (2018) Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions. Pharmacy 6:2, pages 53.
Crossref
Crossref
Moriah J. Brier, Dianne L. Chambless, Jinbo Chen & Jun J. Mao. (2018) Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors. European Journal of Cancer 91, pages 145-152.
Crossref
Crossref
Leah K. Lambert, Lynda G. Balneaves, A. Fuchsia Howard & Carolyn C. Gotay. (2017) Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Research and Treatment 167:3, pages 615-633.
Crossref
Crossref
J. Brett, D. Fenlon, M. Boulton, N.J. Hulbert-Williams, F.M. Walter, P. Donnelly, B. Lavery, A. Morgan, C. Morris & E. Watson. (2018) Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. European Journal of Cancer Care 27:1, pages e12601.
Crossref
Crossref
Lauren A. Marcath, Allison M. Deal, Emily Van Wieren, William Danko, Christine M. Walko, Joseph G. Ibrahim, Karen E. Weck, David R. Jones, Zeruesenay Desta, Howard L. McLeod, Lisa A. Carey, William J. Irvin & Daniel L. Hertz. (2017) Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenetics and Genomics 27:11, pages 402-409.
Crossref
Crossref
Christine Desbiens, Myriam Filion, Marie-Chantale Brien, Jean-Charles Hogue, Christian Laflamme & Julie Lemieux. (2017) Impact of physical activity in group versus individual physical activity on fatigue in patients with breast cancer: A pilot study. The Breast 35, pages 8-13.
Crossref
Crossref
Jo Brett, Nick J Hulbert-Williams, Deborah Fenlon, Mary Boulton, Fiona M Walter, Peter Donnelly, Bernadette Lavery, Adrienne Morgan, Carolyn Morris, Rob Horne & Eila Watson. (2017) Psychometric properties of the Beliefs about Medicine Questionnaire–adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer. Health Psychology Open 4:2, pages 205510291774046.
Crossref
Crossref
Caitriona Cahir, Thomas I. Barron, Linda Sharp & Kathleen Bennett. (2017) Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I–III breast cancer?. Cancer Causes & Control 28:3, pages 215-225.
Crossref
Crossref
Aaron N. WinnNancy L. KeatingStacie B. Dusetzina. (2016) Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. Journal of Clinical Oncology 34:36, pages 4323-4328.
Crossref
Crossref
Xiaoman Liu, Jane Beith, Siew-Kee Low & Alan V Boddy. (2016) The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer. Pharmacogenomics 17:17, pages 1861-1864.
Crossref
Crossref
Aaron N. Winn & Stacie B. Dusetzina. (2016) The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiology and Drug Safety 25:8, pages 953-959.
Crossref
Crossref
Qiu Zhong, Changde Zhang, Qiang Zhang, Lucio Miele, Shilong Zheng & Guangdi Wang. (2015) Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status. BMC Cancer 15:1.
Crossref
Crossref
Caitriona Cahir, Emer Guinan, Stephan U. Dombrowski, Linda Sharp & Kathleen Bennett. (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III breast cancer: A systematic review and meta-analysis. Patient Education and Counseling 98:12, pages 1524-1539.
Crossref
Crossref
Gretchen Kimmick, Sara N. Edmond, Hayden B. Bosworth, Jeffrey Peppercorn, Paul K. Marcom, Kimberly Blackwell, Francis J. Keefe & Rebecca A. Shelby. (2015) Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. The Breast 24:5, pages 630-636.
Crossref
Crossref
Megan C. RobertsStephanie B. WheelerKatherine Reeder-Hayes. (2015) Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review. American Journal of Public Health 105:S3, pages e4-e15.
Crossref
Crossref
N. Lynn Henry & Jennifer J. Griggs. (2015) The Power of the Placebo in Symptom Management. Journal of Clinical Oncology 33:17, pages 1870-1872.
Crossref
Crossref
Kun-Pin Hsieh, Li-Chia Chen, Kwok-Leung Cheung & Yi-Hsin Yang. (2015) Risks of nonadherence to hormone therapy in Asian women with breast cancer. The Kaohsiung Journal of Medical Sciences 31:6, pages 328-334.
Crossref
Crossref
Kun-Pin Hsieh, Li-Chia Chen, Kwok-Leung Cheung & Yi-Hsin Yang. (2015) A competing risk analysis of hormone therapy interruption in Asian women with breast cancer. Pharmacoepidemiology and Drug Safety 24:3, pages 301-309.
Crossref
Crossref
Sarah R. Heisig, Meike C. Shedden‐Mora, Pia von Blanckenburg, Franziska Schuricht, Winfried Rief, Ute‐Susann Albert & Yvonne Nestoriuc. (2014) Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Psycho-Oncology 24:2, pages 130-137.
Crossref
Crossref
Guzyal Gabitova & Nancy J Burke. (2014) Improving healthcare empowerment through breast cancer patient navigation: a mixed methods evaluation in a safety-net setting. BMC Health Services Research 14:1.
Crossref
Crossref
Kenji Taketani, Eriko Tokunaga, Nami Yamashita, Kimihiro Tanaka, Sayuri Akiyoshi, Satoko Okada, Koji Ando, Yasue Kimura, Hiroshi Saeki, Eiji Oki, Masaru Morita, Tetsuya Kusumoto & Yoshihiko Maehara. (2013) The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. Surgery Today 44:10, pages 1841-1846.
Crossref
Crossref
B. B. Reeve, S. A. Mitchell, A. C. Dueck, E. Basch, D. Cella, C. M. Reilly, L. M. Minasian, A. M. Denicoff, A. M. O'Mara, M. J. Fisch, C. Chauhan, N. K. Aaronson, C. Coens & D. W. Bruner. (2014) Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials. JNCI Journal of the National Cancer Institute 106:7, pages dju129-dju129.
Crossref
Crossref
Suhila Sawesi, Janet S. Carpenter & Josette Jones. (2014) Reasons for Nonadherence to Tamoxifen and Aromatase Inhibitors for the Treatment of Breast Cancer: A Literature Review. Clinical Journal of Oncology Nursing 18:3, pages E50-E57.
Crossref
Crossref
N. Lynn Henry. (2014) Endocrine Therapy Toxicity: Management Options. American Society of Clinical Oncology Educational Book:34, pages e25-e30.
Crossref
Crossref
Kimberly R. Jacob Arriola, Tamara A. Mason, Kari Ann Bannon, Carol Holmes, Cecil Lamonte Powell, Kandra Horne & Ruth O’Regan. (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Education and Counseling 95:1, pages 98-103.
Crossref
Crossref
Lorena Rocha Ayres, André de Oliveira Baldoni, Anna Paula de Sá Borges & Leonardo Régis Leira Pereira. (2013) Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. International Journal of Clinical Pharmacy 36:1, pages 45-54.
Crossref
Crossref
K.C. Kadakia & N.L. Henry. (2014) A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer. Breast Diseases: A Year Book Quarterly 25:3, pages 275-277.
Crossref
Crossref
Loretta A Williams, Emre Yucel, Jorge E Cortes & Charles S Cleeland. (2013) Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. Clinical Investigation 3:12, pages 1127-1138.
Crossref
Crossref
A. Morgan & D.R. Fenlon. (2013) Is It Me Or Is It Hot In Here? A Plea For More Research Into Hot Flushes. Clinical Oncology 25:11, pages 681-683.
Crossref
Crossref
Yihang Liu, Jennifer L. Malin, Allison L. Diamant, Amardeep Thind & Rose C. Maly. (2012) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication. Breast Cancer Research and Treatment 137:3, pages 829-836.
Crossref
Crossref
Julia Dunn & Carolyn Gotay. 2013. Hormones and Breast Cancer. Hormones and Breast Cancer
353
375
.
Jun Wu, Dana Stafkey-Mailey & Charles L. Bennett. (2012) Long-term Adherence to Hormone Therapy in Medicaid-enrolled Women with Breast Cancer. Health Outcomes Research in Medicine 3:4, pages e195-e203.
Crossref
Crossref
Caitlin C. Murphy, L. Kay Bartholomew, Melissa Y. Carpentier, Shirley M. Bluethmann & Sally W. Vernon. (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Research and Treatment 134:2, pages 459-478.
Crossref
Crossref
Deborah Watkins BrunerBenjamin MovsasEthan Basch. (2012) Capturing the Patient Perspective: Patient-Reported Outcomes as Clinical Trial Endpoints. American Society of Clinical Oncology Educational Book:32, pages 139-144.
Crossref
Crossref
Kristen D Hadfield & William G Newman. (2012) Pharmacogenetics of aromatase inhibitors. Pharmacogenomics 13:6, pages 699-707.
Crossref
Crossref